


## PHARMACEUTICAL 2022



## DICE Therapeutics Inc. Rank 32 of 466





## PHARMACEUTICAL 2022



## DICE Therapeutics Inc. Rank 32 of 466



The relative strengths and weaknesses of DICE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DICE Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of DICE Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 289%, being 211% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	323,911
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,881
Liabilities, Non-Current	1,916
Other Assets	198
Other Compr. Net Income	-58
Other Expenses	1,492
Other Liabilities	8.0
Other Net Income	136
Other Revenues	1,125
Property and Equipment	1,645
Research and Development	36,506
Selling, General and Administrative Expense	12,222

Output Variable	Value in 1000 USD
Assets	325,754
Liabilities	12,805
Expenses	50,220
Revenues	1,125
Stockholders Equity	312,949
Net Income	-48,959
Comprehensive Net Income	-48,988
Economic Capital Ratio	289%

